StubHub $STUB went public with fanfare then revealed a 143% plunge in free cash flow just weeks later. In this episode of Sue Wall Street, Cassie and Bill break down the class action lawsuit alleging StubHub’s IPO disclosures misled investors by hiding critical financial trends. With big-name underwriters and a 56% stock drop, this one's a must-listen for IPO watchers and retail investors.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

Sprouts Farmers Market $SFM hyped consumer “tailwinds” and raised guidance in July then slashed forecasts three months later, triggering a 26% stock plunge in one day. In this episode of Sue Wall Street, Cassie and Bill dig into the class action lawsuit alleging misleading optimism, ignored internal data, and inflated growth projections. Perfect for retail investors, ESG followers, and anyone tracking grocery sector drama.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

Jayud Global Logistics $JYD soared from $1 to nearly $8—then collapsed 95% overnight. In this episode of Sue Wall Street, we dive into the class action lawsuit alleging a coordinated pump-and-dump scheme, misleading financials, and silence from auditors. With fake stock tips, insider control, and offshore structures, investors say this was built to blow. Perfect for retail traders, audit watchdogs, and market skeptics.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

DeFi Technologies $DEFT promised a low-risk, high-reward crypto arbitrage strategy through its DeFi Alpha desk claiming steady returns and booming growth. But after raising $100M from investors, they quietly admitted those trades weren’t happening. In this episode of Sue Wall Street, Cassie and Bill break down the lawsuit alleging securities fraud, inflated projections, and a CEO exit. For crypto investors, fintech skeptics, and anyone watching the digital asset space.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

Bitdeer Technologies $BTDR hyped its revolutionary SEALMINER A4 chip as a game-changer in Bitcoin mining claiming cutting-edge efficiency and breakthrough innovation. But when the real numbers dropped, the chip underperformed, delays piled up, and the stock plunged over 14% in a day. In this episode of Sue Wall Street, we unpack the lawsuit accusing Bitdeer of misleading investors and inflating expectations. For crypto traders, tech investors, and market skeptics.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

Alexandria Real Estate $ARE touted its Long Island City property as a cornerstone of life sciences growth—until a shocking $323.9M impairment revealed the cracks. In this episode of Sue Wall Street, Cassie and Bill unpack the securities fraud allegations, the alleged “megacampus” misrepresentations, and why investors say they were misled. Perfect for real estate investors, REIT-watchers, and anyone tracking Wall Street transparency.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

Skye Bioscience $SKYE promised a breakthrough obesity drug—but when human trial results dropped, it didn’t even outperform a placebo. The stock plunged 60% in one day, and now executives are accused of cashing out while pumping up investor expectations. This episode of Sue Wall Street breaks down the lawsuit, the science spin, and what it means for biotech investors, traders, and anyone chasing the next pharma moonshot.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

Perrigo $PRGO plunged 25 percent in one day after announcing a full review of its infant formula business—just two years after acquiring it. In this episode of Sue Wall Street, Cassie and Bill unpack how $240M in planned investments, rosy projections, and mounting losses turned into allegations of securities fraud. If you’re an investor, legal buff, or love corporate drama, this one's for you. Expect sharp takes, deep dives, and straight talk on shareholder rights.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

Telix Pharmaceuticals $TLX is facing a federal subpoena and a scorching class action lawsuit after allegedly misleading investors about its prostate cancer drug pipeline and FDA compliance. In this episode of Sue Wall Street, we dive into how missing trial data, shady supply chain claims, and a bombshell FDA rejection sent the stock tumbling. Ideal for biotech investors, legal watchers, and anyone tracking pharmaceutical accountability. Get the facts, not just the filings.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

Primo Brands $PRMB told investors their mega-merger was going “flawlessly” but behind the scenes, tech failures, service chaos, and internal breakdowns were flooding the company. In this episode of Sue Wall Street, we unpack how confident corporate spin turned into a shareholder disaster and triggered a class action lawsuit after a stunning 36% stock drop. If you follow M&A hype, beverage brands, or securities fraud cases, this one’s for you.

Visit ZLK.com for more info.

Add our WhatsApp Channel.